Analysts Offer Predictions for CTXR FY2026 Earnings

Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) – HC Wainwright issued their FY2026 earnings per share estimates for Citius Pharmaceuticals in a report issued on Monday, May 18th. HC Wainwright analyst S. Ramakanth expects that the company will post earnings of ($1.87) per share for the year. HC Wainwright currently has a “Buy” rating and a $4.00 target price on the stock.

A number of other analysts have also commented on the company. D. Boral Capital restated a “buy” rating and issued a $6.00 price target on shares of Citius Pharmaceuticals in a report on Wednesday, March 11th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Citius Pharmaceuticals in a report on Friday, March 27th. Two equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $5.00.

Citius Pharmaceuticals Price Performance

Shares of Citius Pharmaceuticals stock opened at $0.55 on Wednesday. The firm has a market cap of $15.21 million, a price-to-earnings ratio of -0.23 and a beta of 1.05. The stock’s 50-day moving average is $0.77 and its 200-day moving average is $0.90. Citius Pharmaceuticals has a one year low of $0.48 and a one year high of $2.48.

Citius Pharmaceuticals (NASDAQ:CTXR) last issued its quarterly earnings results on Friday, May 15th. The company reported ($0.95) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.67). The firm had revenue of $1.67 million during the quarter, compared to the consensus estimate of $10.23 million.

Institutional Trading of Citius Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of CTXR. XTX Topco Ltd bought a new stake in Citius Pharmaceuticals during the second quarter worth about $32,000. NewEdge Advisors LLC bought a new stake in Citius Pharmaceuticals in the second quarter valued at approximately $40,000. Asset Advisory Group Inc. bought a new stake in Citius Pharmaceuticals in the fourth quarter valued at approximately $46,000. Finally, Heights Capital Management Inc. bought a new stake in Citius Pharmaceuticals in the fourth quarter valued at approximately $622,000. Institutional investors own 16.88% of the company’s stock.

Key Headlines Impacting Citius Pharmaceuticals

Here are the key news stories impacting Citius Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright reiterated a Buy rating on Citius Pharmaceuticals and maintained a $4.00 price target, signaling strong expected upside for the stock. Benzinga
• Neutral Sentiment: The firm also published updated earnings estimates for fiscal 2026 and 2027, forecasting continued losses but without any change to its positive rating outlook. American Banking News
• Neutral Sentiment: Recent reports included detailed quarterly EPS forecasts through 2027, reinforcing that investors are focused on future pipeline and profitability expectations rather than near-term earnings. American Banking News

About Citius Pharmaceuticals

Citius Pharmaceuticals is a clinical‐stage specialty pharmaceutical company focused on the development and commercialization of critical care products and novel drug delivery systems. Headquartered in Cranford, New Jersey, the company aims to address unmet medical needs in acute care, hospital‐acquired infections and subcutaneous delivery of biologics. Citius operates as a Delaware corporation and trades on the NASDAQ under the symbol CTXR.

One of the company’s leading assets is Mino-Lok, an antibiotic lock solution designed to treat catheter‐related bloodstream infections without catheter removal.